Лавентатуг тиведотин

Prop. INN (наименование, предложенное ВОЗ)

3009829-96-0

immunoglobulin G1-kappa, anti-[Homo sapiens SLC39A6 (solute carrier family 39 member 6, solute carrier family 39 (metal ion transporter) member 6, solute carrier family 39 (zinc transporter) member 6, LIV-1, ZIP6)], humanized monoclonal antibody, conjugated on an average of four cysteinyl residues to tivedotin, comprising a cleavable monovalent linker and monomethylauristatin E (MMAE);
H-gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV1-69-2*01 (88.5%) -(IGHD) -IGHJ6*05 (81.8%) K120>Q (112), A127>S (119), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide with L-kappa light chain humanized (1'-219') [V-KAPPA (Homo sapiens IGKV2-29*02 (89.0%) -IGKJ2*01 (91.7%) Q120>G (105'), CDR-IMGT [11.3.9] (27'-37'.55'-57'.94'-102')) (1'-112') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (158'), V101 (196')) (113'-219')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-S, glycoform alfa; substituted at the sulfur atoms of an average of four l-cysteinyl residues among 223, 229, 232, 219', 223'', 229'', 232'' and 219''' with 2-oxo-2-({l-valyl-N⁵-carbamoyl-l-ornithyl[(4-aminophenyl)methoxy]carbonyl-N-methyl-l-valyl-l-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(2R,3R)-N-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanamide}-N^2.1-yl)ethyl (tivedotin) groups

Поделиться этой страницей